CLINICAL_TRIALS
trial_result
· 2020-12-08
Clinical Trial Update: Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea [Phase 2, Phase 3]
Summary
Phase 2/3 trial for fentanyl sublingual spray in exercise-induced breakthrough dyspnea in advanced cancers has completed with posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: M.D. Anderson Cancer Center | Conditions: Advanced Cancers | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2020-12-08